Leiio Wellness Announces Formation of World-Class Advisory Board

Calgary, Alberta–(Newsfile Corp. – May 11, 2021) –   Leiio Wellness Ltd. (“Leiio” or the “Company“), a premium brain performance brand fueled by mushrooms, is pleased to announce the formation of an impressive advisory board consisting of a group of highly respected medical, clinical, technological, regulatory and research experts.

Mauro Zappaterra, MD, PhD brings both medical and clinical expertise to LEIIO. Mauro graduated from Harvard Medical School and specializes in Physical Medicine and Rehabilitation, focusing on optimizing human performance through regenerative medicine, nutrition, mind-body exercises, mind-training, and biofield therapies. He completed his MD/PhD at Harvard, studying neuronal stem cells and the cerebrospinal fluid (CSF) effects in brain development and adults. He has published numerous scientific and medical articles, and his work on the CSF was chosen as the cover image for the prestigious Neuron journal. He combines his training in rehabilitation medicine, evidence-based research, nutrition, and various complementary and alternative medicine modalities such as polarity therapy, reiki and biodynamic craniosacral therapy to work holistically with individuals to optimize their potential and improve their quality of life. He currently directs comprehensive multidisciplinary treatment programs for people with chronic pain and helps them improve their quality of life and increase functional capacity.

Dr. Julia Hoffman is VP of Behavioral Health Strategy at Livongo, a company empowering people with chronic conditions to live better and healthier lives. She was previously the National Director of Mobile Health at the US Department of Veterans Affairs and a Faculty Affiliate at the National Center for Telehealth & Technology, a Defense Center of Excellence. She is a licensed clinical psychologist (CA) who attended Stanford University, completed a Psy.D. in clinical psychology at the PGSP-Stanford Psy.D. Consortium, and a fellowship at Yale University School of Medicine. Julia has led the creation, evaluation, and broad international dissemination of numerous technology-based behavioral health tools. She founded and scaled mobile development for behavioral health at both DoD and VA and has been honored for these efforts by President Barack Obama, the US House of Representatives, the FCC, the American Telemedicine Association, and the American Psychological Association. In addition, Julia brings a technology focus to our advisory board.

Bruce Patsner, MD, JD is a regulatory expert with decades of food and drug law experience. He is a graduate of Amherst College and Baylor College of Medicine in Houston. His post-graduate training was in both Internal Medicine and Ob-Gyn, and later in Gynecologic Oncology. After a successful career in academia and the private sector, he attended Cal Berkeley and Harvard law school. He then went on to a successful stint at CDER/FDA as a Senior Medical Officer. Since leaving the FDA in 2003, he has worked as a Regulatory and Pharmacovigilance consultant on prescription drugs, medical devices, biologicals, dietary supplements, and alternative medical therapies at several medical schools, Genzyme/Sanofi, Legacy Healthcare, and now LEIIO Wellness. In addition, he has taught Food and Drug Law at the University of Houston Law Center and Yonsei University Law School in Seoul, Korea.

Dom D’Agostino Ph.D brings his expertise in research from the involvement in a vast array of professional, academic and personal endeavors. As an Associate Professor with tenure at the University of South Florida, Dom teaches students of the Morsani College of Medicine and the Department of Molecular Pharmacology and Physiology, focusing on medical biochemistry and physiology, neuroscience, and neuropharmacology. In addition, his laboratory develops and tests metabolic-based strategies for targeting CNS oxygen toxicity (seizures), epilepsy, neurodegenerative diseases, and cancer. Before joining the faculty at USF, Dom completed a postdoctoral fellowship in Dom earned his Ph.D. at Robert Wood Johnson Medical School and a B.S. from Rutgers University.

Cory Rosenberg, Leiio’s Co-Founder and Chief Executive Officer, commented, “The team of advisors that the Leiio team can now access is stellar. As a company focused on psychedelic and functional mushrooms, we need specialized advice as we build out our vertically-integrated supply chain and innovation labs, including managing expectations as we see a path to the legalization of psychedelic products.”

Chris Claussen is Leiio’s Co-Founder and Chief of Product and has been investigating the use of functional mushrooms and the promising potential of psilocybin microdose therapies for more than a decade. Chris noted, “The advisory team we have assembled gives the product development and technical team access to a group of scientists with unparalleled research experience in neuroscience, neuroplasticity, neurogenesis and brain wellness. Their immense, combined knowledge in behavioral health, biologicals, dietary supplements, and alternative medical therapies cannot be understated and will be immensely powerful for Leiio.”

ABOUT LEIIO

Leiio is a U.S., vertically integrated, premium brain performance brand fueled by mushrooms. Our vertical supply chain develops and supplies USA-grown, 100% full-fungi functional mushrooms to our in-house consumer brands and a finely curated network of wholesale partners. Pending a DEA license, Leiio will pursue a novel IP and the foundation for a safe, standardized and naturally-derived psilocybin supply chain for distribution to researchers across the U.S.

For additional information, please contact:

Cory Rosenberg
Chief Executive Officer

E: info@Leiio.com
W:Leiiowellness.com

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements which reflect Leiio’s current beliefs and are based on information currently available to Leiio. These statements require Leiio to make assumptions it believes are reasonable and are subject to inherent risks and uncertainties. Actual results and developments may differ materially from the results and developments discussed in the forward-looking statements as certain of these risks and uncertainties are beyond Leiio’s control. Although Leiio believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Leiio can give no assurance that they will prove to be correct.

Leiio intends to focus on optimizing mental performance through mushroom-derived nootropics and psilocybin microdoses. This forward-looking statement is based on certain assumptions including, but not limited to, the expected future legalization of psilocybin and the ability of Leiio to obtain any required regulatory approvals. It is also subject to certain risks including, but not limited to, the risk that psilocybin is not legalized, or is not legalized within a timeframe that allows the company to succeed, the risk that Leiio is unable to obtain necessary regulatory approvals, and the risk that Leiio is not able to raise sufficient capital to execute on its business plan or that its business plan itself is not successful and Leiio is not able to adapt.

Readers are cautioned not to place undue reliance on these forward-looking statements, which are given as of the date hereof, and to not use such forward-looking statements for anything other than their intended purpose. Leiio undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83532